Get the Stockscreener App
34.41
2.41%
-0.835
Alkermes Plc stock is traded at $34.41, with a volume of 1.06M.
It is down -2.41% in the last 24 hours and up +7.60% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$35.24
Open:
$35.58
24h Volume:
1.06M
Relative Volume:
0.68
Market Cap:
$5.68B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
17.64
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
-2.86%
1M Performance:
+7.60%
6M Performance:
+29.43%
1Y Performance:
+20.24%
1-Day Range:
$34.15
$35.58
1-Week Range:
$33.95
$35.68
52-Week Range:
$22.90
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
34.39 | 5.68B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
165.34 | 75.51B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.93 | 47.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.40 | 47.19B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.16 | 17.45B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.23 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Alkermes Plc to Host Earnings Call - ACCESS Newswire
Alkermes plc (NASDAQ:ALKS) Shares Bought by Smartleaf Asset Management LLC - Defense World
Proficio Capital Partners LLC Buys New Stake in Alkermes plc (NASDAQ:ALKS) - Defense World
(ALKS) Technical Pivots with Risk Controls - Stock Traders Daily
What is Zacks Research’s Estimate for Alkermes Q1 Earnings? - Defense World
Zacks Research Predicts Alkermes FY2027 Earnings - Defense World
Y Intercept Hong Kong Ltd Invests $413,000 in Alkermes plc (NASDAQ:ALKS) - MarketBeat
UBS Upgrades Alkermes (ALKS) - Nasdaq
Bank of New York Mellon Corp Has $61.45 Million Stock Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes (NASDAQ:ALKS) Upgraded to Neutral at UBS Group - Defense World
UBS Upgrades Alkermes to Neutral From Sell, $38 Price Target -March 04, 2025 at 08:27 am EST - Marketscreener.com
Alkermes upgraded to Neutral from Sell at UBS - TipRanks
Alkermes plc (ALKS): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
New York State Common Retirement Fund Increases Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World
Ieq Capital LLC Acquires New Stake in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes VP Samuel Parisi sells $65,892 in shares - Investing.com
Alkermes VP Samuel Parisi sells $65,892 in shares By Investing.com - Investing.com UK
Illinois Municipal Retirement Fund Sells 11,878 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes plc (NASDAQ:ALKS) is HealthInvest Partners AB's 10th Largest Position - MarketBeat
C WorldWide Group Holding A S Purchases Shares of 250,000 Alkermes plc (NASDAQ:ALKS) - MarketBeat
Todd Asset Management LLC Sells 30,957 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Sanctuary Advisors LLC Acquires 1,917 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes to Participate in Upcoming Investor Conferences - PR Newswire UK
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire
Blue Trust Inc. Purchases 1,629 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes VP of finance Samuel Joseph Parisi sells shares worth $131,978 By Investing.com - Investing.com South Africa
Alkermes VP of finance Samuel Joseph Parisi sells shares worth $131,978 - Investing.com India
Trading (ALKS) With Integrated Risk Controls - Stock Traders Daily
Alkermes’ Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment (ALKS) - Seeking Alpha
Alkermes plc (NASDAQ:ALKS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Hussman Strategic Advisors Inc. Takes Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Van ECK Associates Corp Purchases 32,581 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes (NASDAQ:ALKS) Hits New 1-Year HighHere's Why - MarketBeat
Alkermes plc (NASDAQ:ALKS) Holdings Reduced by Rice Hall James & Associates LLC - MarketBeat
Alkermes plc VP Samuel Joseph Parisi sells $47,360 in stock By Investing.com - Investing.com South Africa
Alkermes plc VP Samuel Joseph Parisi sells $47,360 in stock - Investing.com India
Craig C. Hopkinson Sells 144,419 Shares of Alkermes plc (NASDAQ:ALKS) Stock - MarketBeat
Alkermes (NASDAQ:ALKS) Price Target Raised to $32.00 - MarketBeat
Opioid Use Disorder Treatment Market Size in the 7MM was around - openPR
Vontobel Holding Ltd. Sells 7,982 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes (NASDAQ:ALKS) Receives "Neutral" Rating from HC Wainwright - MarketBeat
Alkermes (NASDAQ:ALKS) Rating Increased to Strong-Buy at StockNews.com - MarketBeat
Equities Analysts Offer Predictions for Alkermes Q1 Earnings - Defense World
HC Wainwright Issues Negative Estimate for Alkermes Earnings - MarketBeat
Alkermes (ALKS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Alkermes (NASDAQ:ALKS) Updates FY 2025 Earnings Guidance - MarketBeat
Alkermes Plc EPS Soars Past Forecasts - AOL
Alkermes plc Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next - Yahoo Finance
How to Take Advantage of moves in (ALKS) - Stock Traders Daily
Alkermes targets $310M-$340M adjusted EBITDA amid LYBALVI growth and orexin pipeline expansion - MSN
Alkermes (NASDAQ:ALKS) Earns Buy Rating from Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.82%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):